gptkbp:instance_of
|
gptkb:Medicine
|
gptkbp:administered_by
|
catheter
|
gptkbp:administration_time
|
1-2 hours
|
gptkbp:approves
|
gptkb:FDA
|
gptkbp:availability
|
hospital pharmacies
|
gptkbp:clinical_trial
|
ongoing
ongoing studies
|
gptkbp:clinical_use
|
oncology
|
gptkbp:collaborations
|
academic institutions
|
gptkbp:collection
|
clinical registries
|
gptkbp:contains
|
Yttrium-90
|
gptkbp:contraindication
|
severe liver disease
extrahepatic disease
|
gptkbp:developed_by
|
gptkb:Sirtex_Medical
|
gptkbp:dosage_form
|
microspheres
|
gptkbp:duration
|
as needed
single session
|
gptkbp:eligibility
|
good performance status
localized liver tumors
no significant portal hypertension
|
gptkbp:emissions_standard
|
beta radiation
|
gptkbp:events
|
blood tests
imaging studies
|
gptkbp:first_introduced
|
gptkb:2002
|
gptkbp:future_prospects
|
long-term effects
combination therapies
new delivery methods
|
https://www.w3.org/2000/01/rdf-schema#label
|
SIR-Spheres Y-90 resin microspheres
|
gptkbp:invention
|
patented
|
gptkbp:is_targeted_at
|
liver tumors
|
gptkbp:manufacturer
|
gptkb:Australia
|
gptkbp:marketed_as
|
gptkb:SIR-Spheres
|
gptkbp:mechanism_of_action
|
delivers radiation directly to tumors
|
gptkbp:packaging
|
sterile vials
|
gptkbp:price
|
high
|
gptkbp:provides_guidance_on
|
recommended for certain patients
|
gptkbp:recruitment
|
multidisciplinary team
|
gptkbp:regulatory_compliance
|
gptkb:CE_mark
|
gptkbp:research_focus
|
liver cancer treatment
|
gptkbp:route_of_administration
|
intra-arterial
|
gptkbp:safety_features
|
generally well tolerated
|
gptkbp:shelf_life
|
2 years
|
gptkbp:side_effect
|
fatigue
nausea
abdominal pain
liver dysfunction
|
gptkbp:storage
|
room temperature
|
gptkbp:treatment
|
gptkb:hepatocellular_carcinoma
reduced symptoms
monitored over time
improved survival rates
tumor shrinkage
metastatic liver cancer
|
gptkbp:used_for
|
radioembolization
|
gptkbp:bfsParent
|
gptkb:SIR-Spheres
|
gptkbp:bfsLayer
|
9
|